Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells

Cited by (1,001)

Items 901–1,000 of 1,001

1. HIV-1 integration sites in CD4+ T cells during primary, chronic, and late presentation of HIV-1 infection
   Yik Lim Kok, Valentina Vongrad, Sandra E Chaudron, Mohaned Shilaih, Christine Leemann, Kathrin Neumann, Katharina Kusejko, Francesca Di Giallonardo, Herbert Kuster, Dominique L. Braun et al. · 2021 · JCI Insight
2. Substantial uneven proliferation of CD4+ T cells during recovery from acute HIV infection is sufficient to explain the observed expanded clones in the HIV reservoir
   Florencia A. T. Boshier, Daniel B. Reeves, Elizabeth R. Duke, David A. Swan, Martin Prlic, Erwing Fabian Cardozo Ojeda, Joshua Tisdell Schiffer · 2022 · Journal of Virus Eradication
3. Synergistic reactivation of latent HIV-1 provirus by PKA activator dibutyryl-cAMP in combination with an HDAC inhibitor
   Hoyong Lim, Kyung-Chang Kim, Junseock Son, YoungHyun Shin, Cheol‐Hee Yoon, Chun Kang, Byeong‐Sun Choi · 2016 · Virus Research
4. Ultra-Sensitive HIV-1 Latency Viral Outgrowth Assays Using Humanized Mice
   Kimberly P. Schmitt, Ramesh Akkina · 2018 · Frontiers in Immunology
5. High frequency CCR5 editing in human hematopoietic stem progenitor cells protects xenograft mice from HIV infection
   Claiborne, Daniel T., Detwiler, Zachary, Docken, Steffen S., Borland, Todd D., Cromer, Deborah, Simkhovich, Amanda, Ophinni, Youdiil, Okawa, Ken, Bateson, Timothy, Chen, Tao et al. · 2025 · Nature Communications
6. Tracking replication-competent HIV reservoirs in infected individuals
   Tae‐Wook Chun · 2013 · Current Opinion in HIV and AIDS
7. Why cure, why now?
   Daniel R. Kuritzkes · 2016 · Journal of Medical Ethics
8. Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients
   Geoffrey T. Ivison, Elena Vendrame, Giovanny J. Martínez-Colón, Thanmayi Ranganath, Rosemary Vergara, Nancy Q. Zhao, Maureen P. Martin, Sean C. Bendall, Mary N Carrington, Joshua C. Cyktor et al. · 2022 · Frontiers in Cellular and Infection Microbiology
9. HIV cure strategies: which ones are appropriate for Africa?
   Christopher Zaab-Yen Abana, Helena Lamptey, Evelyn Yayra Bonney, George B. Kyei · 2022 · Cellular and Molecular Life Sciences
10. IL-15 and N-803 for HIV Cure Approaches
    J. Natalie Howard, Alberto Bosque · 2023 · Viruses
11. HIV-1 infection of genetically engineered iPSC-derived central nervous system-engrafted microglia in a humanized mouse model
    Alice K. Min, Behnam Javidfar, Roy D. Missall, Donald Doanman, Madel Durens, Samantha St Vil, Zahra Masih, Mara Graziani, Annika Mordelt, Samuele G. Marro et al. · 2023 · Journal of Virology
12. Mathematical Modeling of HIV-1 Infection and Drug Therapy
    Libin Rong, Zhilan Feng, Alan S. Perelson · 2008 · Springer eBooks
13. Attacking the HIV Reservoir from the Immune and Viral Perspective
    Marta Massanella, Javier Martínez‐Picado, Julià Blanco · 2012 · Current HIV/AIDS Reports
14. HIV Eradication: Combinatorial Approaches to Activate Latent Viruses
    Elisa De Crignis, Tokameh Mahmoudi · 2014 · Viruses
15. Therapy for persistent HIV
    Kara S. Keedy, David M. Margolis · 2010 · Trends in Pharmacological Sciences
16. Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy
    Almudena Torres-Cornejo, Omar J. BenMarzouk‐Hidalgo, Alicia Gutiérrez‐Valencia, Pilar Pérez‐Romero, Reyes Martín-Peña, Rosa Ruiz-Valderas, Pompeyo Viciana, Luis Fernando López-Cortés · 2013 · AIDS
17. Detection of HIV-1 at between 20 and 49 Copies per Milliliter by the Cobas TaqMan HIV-1 v2.0 Assay Is Associated with Higher Pretherapy Viral Load and Less Time on Antiretroviral Therapy
    José Francisco Pascual Pareja, Lorena Martínez‐Prats, Joanna Luczkowiak, Silvana Fiorante, Rafael Rubio, Federico Pulido, Joaquín R. Otero, Rafael Bastos Delgado · 2010 · Journal of Clinical Microbiology
18. HIV-infected cells are frequently clonally expanded after prolonged antiretroviral therapy: implications for HIV persistence
    Frank M. Maldarelli · 2015 · Journal of Virus Eradication
19. Molecular Control of HIV and SIV Latency
    Gilles Darcis, Benoît Van Driessche, Sophie Bouchat, Frank Kirchhoff, Carine M. Van Lint · 2017 · Current topics in microbiology and immunology
20. Extracellular vesicle-mediated intercellular communication in HIV-1 infection and its role in the reservoir maintenance
    Eleonora Olivetta, Chiara Chiozzini, Claudia Arenaccio, Francesco Manfredi, Flavia Ferrantelli, Maurizio Federico · 2019 · Cytokine & Growth Factor Reviews
21. An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells
    Qian Wang, Shan Su, Jing Xue, Fei Yu, Jing Pu, Wenwen Bi, Shuai Xia, Yu Meng, Cong Wang, Wenqian Yang et al. · 2020 · Science Translational Medicine
22. Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response
    Lorna Leal, Csaba Fehér, Valèria Richart, Berta Torres, Felipe García · 2020 · Vaccines
23. The Cellular Thioredoxin-1/Thioredoxin Reductase-1 Driven Oxidoreduction Represents a Chemotherapeutic Target for HIV-1 Entry Inhibition
    Kathrin Reiser, Leen Mathys, Sophie Curbo, Christophe C. Pannecouque, Sam Noppen, Sandra Liekens, Lars Engman, Mathias Lundberg, Jan M. Balzarini, Anna Karlsson · 2016 · PLoS ONE
24. The evaluation of risk-benefit ratio for gut tissue sampling in HIV cure research
    Vikram Mehraj, Peter Ghali, Rayoun Ramendra, Cecilia Theresa Costiniuk, Bertrand Lebouché, Rosalie Ponte, Robert J. Reinhard, José Sousa, Nicolas Chomont, Éric A. Cohen et al. · 2017 · Journal of Virus Eradication
25. A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection
    Jamie F. S. Mann, Joshua Pankrac, Katja Klein, Paul F. McKay, Deborah F. L. King, Richard M. Gibson, Chanuka N. Wijewardhana, Rahul Pawa, Jodi Meyerowitz, Yong Gao et al. · 2020 · EBioMedicine
26. Treatment Implications of the Latent Reservoir for HIV‐1
    Susan Peterson, Alison P. Reid, Scott Y. H. Kim, Robert F. Siliciano · 2007 · Advances in pharmacology
27. Temporarily controlled HIV-1 replication after intravenous immunoglobulin treatment of Guillain-Barré syndrome
    Magnus Gisslén, Pam Fredman, Dietmar Fuchs, Annika Y. Lekman, Lars Rosengren · 2005 · Scandinavian Journal of Infectious Diseases
28. Genetic therapy for HIV/AIDS
    Ananthalakshmi Poluri, Marc van Maanen, Richard E. Sutton · 2003 · Expert Opinion on Biological Therapy
29. Intracellular Metabolism and Persistence of the Anti-Human Immunodeficiency Virus Activity of 2′,3′-Didehydro-3′-Deoxy-4′-Ethynylthymidine, a Novel Thymidine Analog
    Elijah Paintsil, Ginger E. Dutschman, Rong Hu, Susan P. Grill, Wing Lam, Masanori Baba, Hiromichi Tanaka, Yung‐Chi Cheng · 2007 · Antimicrobial Agents and Chemotherapy
30. HIV and Interferon Regulatory Factor 1: A Story of Manipulation and Control
    Aida Sivro, Ruey‐Chyi Su, Francis Allan Plummer, Terry Blake Ball · 2013 · AIDS Research and Human Retroviruses
31. Establishment of Drug‐Resistant HIV‐1 in Latent Reservoirs
    Viktor Dahl, Sarah Palmer · 2009 · The Journal of Infectious Diseases
32. The Immunology of Human Immunodeficiency Virus Infection
    Susan L. Moir, Mark Connors, Anthony S. Fauci · 2015 · Elsevier eBooks
33. Persistence of Lamivudine-Sensitive HIV-1 Quasispecies in the Presence of Lamivudine In Vitro and In Vivo
    Kristina Allers, Stefanie Andrea Knoepfel, Pia Rauch, Hauke Walter, Milos Opravil, Marek Fischer, Huldrych F. Günthard, Karin Jutta Metzner · 2007 · JAIDS Journal of Acquired Immune Deficiency Syndromes
34. Human Immunodeficiency Virus Type 1 (HIV-1) Antigen Secretion by Latently Infected Resting CD4 + T Lymphocytes from HIV-1-Infected Individuals
    Jean-Michel Fondere, Gaël Petitjean, Marie‐France Huguet, Sharon Lynn Salhi, Vincent Baillat, Anna Macura-Biegun, Pierre Becquart, Jacques Reynes, Jean-Pierre Vendrell · 2004 · Journal of Virology
35. Phenotyping Viral Reservoirs to Reveal HIV-1 Hiding Places
    Wenxuan Chen, Ben Berkhout, Alexander O. Pasternak · 2025 · Current HIV/AIDS Reports
36. Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs
    Pierre Gantner, Guinevere Q. Lee, David Rey, Thibault Mésplède, Marialuisa Partisani, Christine Cheneau, Geneviève Beck-Wirth, Jean-Pierre Faller, Mahsa Mohseni-Zadeh, Martin Martinot et al. · 2017 · Journal of Antimicrobial Chemotherapy
37. Viral and Host Biomarkers of HIV Remission Post Treatment Interruption
    Leila B. Giron, Mohamed Abdel‐Mohsen · 2022 · Current HIV/AIDS Reports
38. HIV-1 Tat Upregulates TREM1 Expression in Human Microglia
    Grant R. Campbell, Pratima Rawat, Rachel K. To, Stephen A. Spector · 2023 · The Journal of Immunology
39. Identifying physiological tissue niches that support the HIV reservoir in T cells
    Nnamdi M. Ikeogu, Oluwaseun Ajibola, Romaniya Zayats, Thomas T. Murooka · 2023 · mBio
40. HIV-PULSE: a long-read sequencing assay for high-throughput near full-length HIV-1 proviral genome characterization
    Laurens Lambrechts, Noah Bonine, Rita Verstraeten, Marion Pardons, Ytse Noppe, Sofie Rutsaert, Filip Van Nieuwerburgh, Wim Van Criekinge, Basiel Cole, Linos Vandekerckhove · 2023 · Nucleic Acids Research
41. Cognate antigen engagement induces HIV-1 expression in latently infected CD4+ T cells from people on long-term antiretroviral therapy
    Milica Moskovljevic, Filippo Dragoni, Nathan L. Board, Fengting Wu, Jun Lai, Hao Zhang, James Robert White, Rebecca Hoh, Kenneth Lynn, Pablo Tebas et al. · 2024 · Immunity
42. Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment
    Carolina Gutiérrez, Beatriz Hernández‐Novoa, Alejandro Vallejo, Sergio Serrano Villar, María Abad-Fernández, Nadia Madrid, Laura Díaz, Ana Maria Moreno, Fernando Dronda, Javier Zamora et al. · 2013 · AIDS
43. Supranormal thymic output up to 2 decades after HIV-1 infection
    Christian R. Aguilera-Sandoval, Otto O. Yang, Nebojša Jojić, Pietro Lovato, Diana Yu Hui Chen, Maria Ines Boechat, Paige Cooper, Jun Zuo, Christina M. Ramirez, Marvin E. Belzer et al. · 2016 · AIDS
44. HIV-1 reservoir dynamics in CD4+ T cells
    Katherine M. Bruner, Lillian B. Cohn · 2018 · Current Opinion in HIV and AIDS
45. Monitoring HIV DNA and cellular activation markers in HIV-infected humanized mice under cART
    Mary-Aude Rochat, Erika Schlaepfer, Stefan P. Kuster, Duo Li, Annette Audigé, Sandra Ivic, Audrey Fahrny, Roberto F. Speck · 2018 · Virology Journal
46. Tat IRES modulator of tat mRNA (TIM-TAM): a conserved RNA structure that controls Tat expression and acts as a switch for HIV productive and latent infection
    Georges Khoury, Charlene Mackenzie, Lilia Ayadi, Sharon R. Lewin, Christiane Branlant, Damian F. J. Purcell · 2019 · Nucleic Acids Research
47. Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment
    Christian Thorball, Alessandro Borghesi, Nadine Bachmann, Chantal von Siebenthal, Valentina Vongrad, Teja Turk, Kathrin Neumann, Niko Beerenwinkel, Jasmina Bogojeska, Volker Röth et al. · 2020 · JAIDS Journal of Acquired Immune Deficiency Syndromes
48. Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy
    Lorena Vigón, Paula Martínez-Román, Sara Rodríguez-Mora, Montserrat Torres, Maria Carmen Puertas, Elena Mateos, María Salgado, Antonio Navarro, Matilde Sánchez‐Conde, Juan Ambrosioni et al. · 2021 · Biochemical Pharmacology
49. Cell-Associated Human Immunodeficiency Virus (HIV) Ribonucleic Acid Has a Circadian Cycle in Males With HIV on Antiretroviral Therapy
    Jared Stern, Ajantha E. Solomon, Ashanti Dantanarayana, Rachel D. Pascoe, Arnold Reynaldi, Miles P. Davenport, Jeffrey M. Milush, Steven G. Deeks, Wendy Hartogensis, Frederick M. Hecht et al. · 2021 · The Journal of Infectious Diseases
50. Development of Droplet Digital PCR-Based Assays to Quantify HIV Proviral and Integrated DNA in Brain Tissues from Viremic Individuals with Encephalitis and Virally Suppressed Aviremic Individuals
    Hye Kyung Chung, Julian B. Hattler, Jigna Narola, Harita Babbar, Yanhui Cai, Mohamed Abdel‐Mohsen, Woong‐Ki Kim · 2022 · Microbiology Spectrum
51. Impact of Cannabis Use on Immune Cell Populations and the Viral Reservoir in People With HIV on Suppressive Antiretroviral Therapy
    Shane D. Falcinelli, Alicia D. Volkheimer, Lesia Semenova, Ethan Wu, Alexander Richardson, Manickam Ashokkumar, David M. Margolis, Nancie M. Archin, Cynthia D Rudin, David M. Murdoch et al. · 2023 · The Journal of Infectious Diseases
52. Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment Naïve HIV-1–Infected Patients
    Arvid Edén, Lars‐Magnus Andersson, Örjan Andersson, Leo Flamholc, Filip Josephson, Staffan Nilsson, Vidar Ormaasen, Veronica Svedhem, Christer Säll, Anders B. Sönnerborg et al. · 2010 · AIDS Research and Human Retroviruses
53. Involvement of Sp1 in Butyric Acid-Induced HIV-1 Gene Expression
    Kenichi Imai, Takashi Okamoto, Kuniyasu Ochiai · 2015 · Cellular Physiology and Biochemistry
54. The HIV cure research agenda: the role of mathematical modelling and cost-effectiveness analysis
    Kenneth A. Freedberg, Cristina de Albuquerque Possas, Steven G. Deeks, Anna-Laura Ross, Katherine L. Rosettie, Michele Di Mascio, Chris Collins, Rochelle P. Walensky, Yazdan Yazdanpanah · 2015 · Journal of Virus Eradication
55. How Unavoidable Are Analytical Treatment Interruptions in HIV Cure–Related Studies?
    David M. Margolis, Steven G. Deeks · 2019 · The Journal of Infectious Diseases
56. Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection
    Lorena Vigón, Sara Rodríguez-Mora, Alejandro Luna, Virginia Sandonís, Elena Mateos, Guiomar Bautista, Juan Luis Steegmann, Núria Climent, Montserrat Plana, Pilar Pérez‐Romero et al. · 2020 · Biochemical Pharmacology
57. Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation
    Po-Ting Liu, Brandon F. Keele, Peter Abbink, Noe B. Mercado, Jinyan Liu, Esther Apraku Bondzie, Abishek Chandrashekar, Erica N. Borducchi, Joseph Hesselgesser, Michael Mish et al. · 2020 · Nature Communications
58. Anti HIV-1 and antimicrobial activity of the leaf extracts of Calotropis procera
    Remya Mohanraj, Jyotirmoy Rakshit, Malcolm Nobre · 2010 · International Journal of Green Pharmacy
59. Treatment of acute HIV-1 infection: are we getting there?
    Cristina Cellerai, Susan J. Little, Sabine Kinloch‐de Loes · 2008 · Current Opinion in HIV and AIDS
60. A review on infection with human immunodeficiency virus
    Kaveh Manavi · 2006 · Best Practice & Research Clinical Obstetrics & Gynaecology
61. Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy
    Bernard Masquelier, A. Taïeb, Sandrine Reigadas, B. Marchou, C. Cheneau, Bruno Spire, Charlotte Charpentier, Catherine Leport, François Raffi, Geneviève Chêne et al. · 2011 · Journal of Antimicrobial Chemotherapy
62. Rekindled HIV infection
    Janet D'Angelo Siliciano, Robert F. Siliciano · 2014 · Science
63. Towards a new combination therapy with vectored immunoprophylaxis for HIV: Modeling “shock and kill” strategy
    Qi Deng, Ting Guo, Zhipeng Qiu, Yuming Chen · 2022 · Mathematical Biosciences
64. Ponatinib Represses Latent HIV-1 by Inhibiting AKT-mTOR
    Ting Huang, Jinfeng Cai, Peipei Wang, Jiasheng Zhou, Haitao Zhang, Ziqi Wu, Jiacong Zhao, Zhanlian Huang, Kai Deng · 2023 · Antimicrobial Agents and Chemotherapy
65. Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors
    Gautam Kumar Sahu, Miles W. Cloyd · 2011 · Virology Journal
66. Designed Transcription Activator-Like Effector Proteins Efficiently Induced the Expression of Latent HIV-1 in Latently Infected Cells
    Xiaohui Wang, Pengfei Wang, Zheng Fu, Haiyan Ji, Xiying Qu, Hanxian Zeng, Xiaoli Zhu, Junxiao Deng, Panpan Lu, Shijun Zha et al. · 2014 · AIDS Research and Human Retroviruses
67. Discovery of a Distinct Chemical and Mechanistic Class of Allosteric HIV-1 Integrase Inhibitors with Antiretroviral Activity
    Christine Burlein, Cheng Wang, Min Xu, Triveni Bhatt, Mark W. Stahlhut, Yangsi Ou, Gregory C. Adam, Jeffrey Heath, Daniel J. Klein, John M. Sanders et al. · 2017 · ACS Chemical Biology
68. Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test
    Linda L. Jagodzinski, Mark Manak, Holly R. Hack, Ying Liu, Jennifer A. Malia, Joanna Freeman, Nittaya Phanuphak, Mark S. de Souza, Eugene D. M. B. Kroon, Donn J. Colby et al. · 2019 · Journal of Clinical Microbiology
69. Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
    María Rosa López‐Huertas, Carolina Gutiérrez, Nadia Madrid-Elena, Beatriz Hernández‐Novoa, Julián Olalla, Montserrat Plana, Rafael Bastos Delgado, Rafael Rubio, María Ángeles Muñoz‐Fernández, Santiago Moreno · 2020 · Scientific Reports
70. A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators
    Kouki Matsuda, Takuya Kobayakawa, Ryusho Kariya, K. Tsuchiya, Shoraku Ryu, Kohei Tsuji, Takahiro M. Ishii, Hiroyuki Gatanaga, Kazuhisa Yoshimura, Seiji Okada et al. · 2021 · Frontiers in Microbiology
71. Inducible HIV-1 Reservoir Quantification: Clinical Relevance, Applications and Advancements of TILDA
    Cynthia Lungu, Riddhima Banga, Rob A. Gruters, Francesco A. Procopio · 2021 · Frontiers in Microbiology
72. Proviral Turnover During Untreated HIV Infection Is Dynamic and Variable Between Hosts, Impacting Reservoir Composition on ART
    Kelsie Brooks, F. Harrison Omondi, Richard H. Liang, Hanwei Sudderuddin, Bradley R. Jones, Jeffrey B. Joy, Chanson J. Brumme, Eric Hunter, Zabrina L. Brumme · 2021 · Frontiers in Microbiology
73. Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels
    Michelle Wong, Yulong Wei, Ya‐Chi Ho · 2023 · Current Opinion in HIV and AIDS
74. The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy
    Cynthia L. Gay, Patrick J. Hanley, Shane D. Falcinelli, JoAnn D. Kuruc, Susan Pedersen, Jennifer Kirchherr, Samuel L M Raines, Cecilia M. Motta, Chris Lazarski, Pamela A. Chansky et al. · 2024 · The Journal of Infectious Diseases
75. Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients
    Fatema A. Legrand, Jacob Abadi, Kimberly A. Jordan, Miles P. Davenport, Steven G. Deeks, Glenn J. Fennelly, ANDREW A. WIZNIA, Douglas F. Nixon, Michael G Rosenberg · 2005 · AIDS
76. Humanized mouse models of latent HIV infection
    Maud Déruaz, Andrew Martin Tager · 2017 · Current Opinion in Virology
77. From Berlin to London: HIV-1 Reservoir Reduction Following Stem Cell Transplantation
    Cecilia A. Prator, Joanna L. Donatelli, Timothy J. Henrich · 2020 · Current HIV/AIDS Reports
78. HIV Latency and the Noncoding RNA Therapeutic Landscape
    Sheena M. Saayman, Thomas C. Roberts, Kevin V. Morris, Marc S. Weinberg · 2015 · Advances in experimental medicine and biology
79. Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment
    Shuangjie Zhang, Ard van Sighem, Luuk A. Gras, Peter Reiss, Colette Smit, Frank P. Kroon, Suzanne Jurriaans, Jan M. Prins, Joep M. A. Lange, Frank de Wolf · 2010 · Antiviral Therapy
80. Computational modeling of tetrahydroimidazo‐[4,5,1‐jk][1,4]‐benzodiazepinone derivatives: An atomistic drug design approach using Kier‐Hall electrotopological state (E‐state) indices
    Nitin S. Sapre, Nilanjana Pancholi, Swagata Gupta, Neelima Sapre · 2008 · Journal of Computational Chemistry
81. Confirmation of HIV-like sequences in respiratory tract bacteria of Cambodian and Kenyan HIV-positive pediatric patients
    Vladimír Zajac, Lenka Matelova, Anna Líšková, Michal Mego, Vladimir Holec, Zuzana Adamcikova, Viola Števurková, Andrea Shahum, Vladimir Krcmery · 2011 · Medical Science Monitor
82. Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV
    Tomas Mellberg, Veronica D. Gonzalez, Annica Lindkvist, Arvid Edén, Anders B. Sönnerborg, Johan K. Sandberg, Bo Svennerholm, Magnus Gisslén · 2011 · AIDS Research and Therapy
83. Blood and Guts and HIV: Preferential HIV Persistence in GI Mucosa
    Steven A. Yukl, Joseph K. Wong · 2008 · The Journal of Infectious Diseases
84. Confronting proviral HIV infection
    David M. Margolis · 2007 · Current HIV/AIDS Reports
85. Current and emerging therapies to combat persistent intracellular pathogens
    Philip Arandjelovic, Marcel Doerflinger, Marc Pellegrini · 2019 · Current Opinion in Pharmacology
86. IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis
    Rui André Saraiva Raposo, Miguel de Mulder Rougvie, Dominic Paquin‐Proulx, Phillip M. Brailey, Vinicius D. Cabido, Paul M. Zdinak, Allison S. Thomas, Szu-Han Huang, Greta A. Beckerle, Richard Brad Jones et al. · 2017 · JCI Insight
87. Integrated analysis of viral blips, residual viremia, and associated factors in people with HIV: Results from a retrospective cohort study
    Patrick G. A. Oomen, Suzan Dijkstra, Laura Marije Hofstra, Monique Nijhuis, Annelies Verbon, Tania Mudrikova, Annemarie M. J. Wensing, Andy I. M. Hoepelman, Berend J. van Welzen · 2023 · Journal of Medical Virology
88. Targeting the HIV reservoir: chimeric antigen receptor therapy for HIV cure
    Shuang Li, Hu Wang, Na Guo, Bin Su, Olivier Lambotte, Tong Zhang · 2023 · Chinese Medical Journal
89. Biomarkers of HIV replication
    Janet D'Angelo Siliciano, Robert F. Siliciano · 2010 · Current Opinion in HIV and AIDS
90. Human Immunodeficiency Virus Playing Hide-and-Seek: Understanding the TFH Cell Reservoir and Proposing Strategies to Overcome the Follicle Sanctuary
    Yew Ann Leong, Anurag Atnerkar, Di Yu · 2017 · Frontiers in Immunology
91. Quantification of Viral RNA and DNA Positive Cells in Tissues From Simian Immunodeficiency Virus/Simian Human Immunodeficiency Virus Infected Controller and Progressor Rhesus Macaques
    Bapi Pahar, Dot Kuebler, Terri Rasmussen, Xiaolei Wang, Sudesh Srivastav, Arpita Das, Ronald S. Veazey · 2019 · Frontiers in Microbiology
92. Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal
    James H. McMahon, Vanessa A. Evans, Jillian S.Y. Lau, Jori Symons, Jennifer M. Zerbato, J. Judy Chang, Ajantha Solomon, Surekha Tennakoon, Ashanti Dantanarayana, Michelle Hagenauer et al. · 2021 · AIDS
93. Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection
    Ruojing Bai, Shiyun Lv, Hao Wu, Lili Dai · 2022 · Disease Markers
94. Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks
    Lisa Jörimann, Jasmin Tschumi, Marius Zeeb, Christine Leemann, Corinne D Schenkel, Kathrin Neumann, Sandra E Chaudron, Maryam Zaheri, Paul Frischknecht, Nadia Neuner-Jehle et al. · 2023 · The Journal of Infectious Diseases
95. Design and Implementation of a Randomized Crossover Study of Valproic Acid and Antiretroviral Therapy to Reduce the HIV Reservoir
    Jean‐Pierre Routy, Jonathan Benjamin Angel, Johanna N. Spaans, Benoît Trottier, Danielle Rouleau, Jean-Guy Baril, Marianne Harris, Sylvie Trottier, Joel Singer, Nicolas Chomont et al. · 2012 · HIV Clinical Trials
96. Stochastic modelling of viral blips in HIV-1-infected patients: Effects of inhomogeneous density fluctuations
    Daniel Sánchez‐Taltavull, Tomás Alarcón · 2015 · Journal of Theoretical Biology
97. Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration
    Dai Watanabe, Shiro Ibe, Tomoko Uehira, Rumi Minami, Atsushi Sasakawa, Keishiro Yajima, Hitoshi Yonemoto, Hiroki Bando, Yoshihiko Ogawa, Tomohiro Taniguchi et al. · 2011 · BMC Infectious Diseases
98. HIV RNA and proviral HIV DNA can be detected in semen after 6 months of antiretroviral therapy although HIV RNA is undetectable in blood
    Peiwei Du, An Liu, Yanmei Jiao, Cuie Liu, Taiyi Jiang, Weijun Zhu, Yunxia Zhu, Hao Wu, Lijun Sun · 2016 · Microbiology and Immunology
99. Intracellular HIV-1 RNA and CD4+ T-cell activation in patients starting antiretrovirals
    Ramy El–Diwany, Florian P. Breitwieser, Mary Soliman, Alyza M. Skaist, Geetha Srikrishna, Joel N. Blankson, Stuart C. Ray, Sarah J. Wheelan, David L. Thomas, Ashwin Balagopal · 2017 · AIDS
100. Polymeric Therapeutic Delivery Systems for the Treatment of Infectious Diseases
     Blessing A. Aderibigbe · 2017 · Therapeutic Delivery